Bipolar Disorder – Landscape & Forecast – Disease Landscape & Forecast
Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the mainstay therapies used to treat BPD; their long-standing stronghold as patient-share leaders contribute to the challenges that branded therapies face entering this crowded therapy market. Nevertheless, current treatments have multiple shortcomings; thus, novel therapies with the potential to capitalize on the remaining opportunities in BPD treatment could drive growth of this market. In addition to newer-to-market antipsychotics (e.g., Alkermes’s Lybalvi, Intra-Cellular Therapies’ Caplyta), a handful of emerging therapies from a variety of drug classes are in late-phase development (e.g., Vanda Pharmaceuticals’ iloperidone, NeuroRx’s NRX-101, Sunovion / Sumitomo Dainippon / Otsuka’s SEP-4199), and still more are in early development (e.g., psychedelics). If successful, they could offer new treatment options for BPD.
Questions answered
- What is the current size of the BPD therapy market in the G7 countries? What key events will influence the market over the next decade?
- What is the epidemiology of BPD in the G7 countries? What percentage of prevalent patients are diagnosed and drug-treated?
- What factors drive and constrain the use of branded atypical antipsychotics in the treatment of BPD? Which branded therapy is expected to experience the most commercial success during the forecast period?
- What are the greatest areas of unmet need in the treatment of BPD, and how are emerging therapies expected to address these unmet needs?
Geographies: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this research
Epidemiology: Lifetime prevalence, diagnosed prevalence, and drug-treated prevalence of BPD by country
Forecast: 10-year, annualized, drug-level sales and patient share of key BPD therapies through 2032, segmented by brands / generics
Emerging therapies: Phase 3: 4 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Bipolar Disorder - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Bipolar Disorder - Key Findings - September 2023
- Key Updates
- September 2023
- Market Outlook
- Key findings
- Market share of drug classes for bipolar disorder: 2022
- Market share of drug classes for bipolar disorder: 2032
- Bipolar disorder SWOT analysis
- Market drivers and constraints
- What factors are driving the market for bipolar disorder?
- What factors are constraining the market for bipolar disorder?
- Drug-class-specific trends
- Major-market sales of key antiepileptic drugs in bipolar disorder: 2022-2032
- Patient share of key antiepileptic drugs for bipolar disorder in the United States: 2022-2032
- Patient share of key antiepileptic drugs for bipolar disorder in the EU5: 2022-2032
- Patient share of key antiepileptic drugs for bipolar disorder in Japan: 2022-2032
- Major-market sales of key oral atypical antipsychotics in bipolar disorder: 2022-2032
- Patient share of key oral atypical antipsychotics for bipolar disorder in the United States: 2022-2032
- Patient share of key oral atypical antipsychotics for bipolar disorder in the EU5: 2022-2032
- Patient share of key oral atypical antipsychotics for bipolar disorder in Japan: 2022-2032
- Major-market sales of LAIs of key atypical antipsychotics in bipolar disorder: 2022-2032
- Patient share of LAIs of key atypical antipsychotics for bipolar disorder in the United States: 2022-2032
- Patient share of LAIs of atypical antipsychotics for bipolar disorder in the EU5: 2022-2032
- Patient share of LAIs of atypical antipsychotics for bipolar disorder in Japan: 2022-2032
- Alpha2a adrenergic receptor agonists
- Sales of dexmedetomidine sublingual film (Igalmi) in bipolar disorder in the United States: 2022-2032
- Patient share of dexmedetomidine sublingual film (Igalmi) in bipolar disorder in the United States: 2022-2032
- Major-market sales of antidepressants in bipolar disorder: 2022-2032
- Patient share of antidepressants for bipolar disorder in the United States: 2022-2032
- Patient share of antidepressants for bipolar disorder in the EU5: 2022-2032
- Patient share of antidepressants for bipolar disorder in Japan: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions - Bipolar Disorder (2022-2032) - September 2023
- Market Forecast Dashboard - Bipolar Disorder (2022-2032) - September 2023
- Etiology and Pathophysiology
- Disease overview
- Genetic factors
- Genes linked to bipolar disorder
- Environmental factors
- Key pathways and drug targets
- Etiology and pathophysiology of bipolar disorder: levels of understanding
- Key pathways in bipolar disorder
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Total lifetime prevalent cases of bipolar disorder: 2022-2032
- Diagnosed lifetime prevalent cases of bipolar disorder: 2022-2032
- Drug-treated cases of bipolar disorder in the major pharmaceutical markets: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for bipolar disorder
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for bipolar disorder
- Current treatments used for bipolar disorder
- Advantages and disadvantages of lithium
- Expert insight: lithium
- Advantages and disadvantages of valproic acid
- Expert insight: valproic acid
- Advantages and disadvantages of lamotrigine
- Expert insight: lamotrigine
- Advantages and disadvantages of carbamazepine
- Expert insight: carbamazepine
- Advantages and disadvantages of aripiprazole
- Expert insight: aripiprazole
- Advantages and disadvantages of asenapine
- Expert insight: asenapine
- Advantages and disadvantages of brexpiprazole
- Expert insight: brexpiprazole
- Advantages and disadvantages of cariprazine
- Expert insight: cariprazine
- Advantages and disadvantages of lumateperone
- Expert insight: lumateperone
- Advantages and disadvantages of lurasidone
- Expert insight: lurasidone
- Advantages and disadvantages of oral olanzapine
- Advantages and disadvantages of Lybalvi
- Expert insight: olanzapine
- Advantages and disadvantages of quetiapine
- Expert insight: quetiapine
- Advantages and disadvantages of long-acting injectables
- Expert insight: long-acting injectables
- Advantages and disadvantages of antidepressants
- Expert insight: antidepressants
- Igalmi
- Advantages and disadvantages of Igalmi
- Expert insight: Igalmi
- Medical practice
- Overview
- Factors influencing drug selection in bipolar disorder
- Region-specific treatment practices
- Treatment decision tree for bipolar disorder: United States
- Treatment decision tree for bipolar disorder: Europe
- Treatment decision tree for bipolar disorder: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in bipolar disorder
- Top unmet needs in bipolar disorder: current and future attainment
- Expert insight: unmet need in bipolar disorder
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for bipolar disorder
- Estimated launch dates of key emerging therapies for the treatment of bipolar disorder
- Iloperidone profile
- Analysis of the clinical development program for iloperidone
- Expert insight: iloperidone
- Expectations for launch and sales opportunity of iloperidone in bipolar disorder
- SEP-4199 profile
- Analysis of the clinical development program for SEP-4199
- Expert insight: SEP-4199
- Expectations for launch and sales opportunity of SEP-4199 in bipolar disorder
- Risperidone oral weekly (LYN-005) profile
- Analysis of the clinical development program for risperidone oral weekly (LYN-005)
- Expectations for launch and sales opportunity of risperidone oral weekly (LYN-005) in bipolar disorder
- NRX-101 profile
- Analysis of the clinical development program for NRX-101
- Expert insight: NRX-101
- Expectations for launch and sales opportunity of NRX-101 in bipolar disorder
- Endoxifen profile
- Analysis of the clinical development program for endoxifen
- Expectations for launch and sales opportunity of endoxifen in bipolar disorder
- Early-phase pipeline analysis
- Select compounds in early-phase development for bipolar disorder
- Key findings
- Access and Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in bipolar disorder: United States
- General reimbursement environment: United States
- Key market access considerations in bipolar disorder: EU5
- General reimbursement environment: EU5
- Key market access considerations in bipolar disorder: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Bipolar disorder bibliography
- Key Findings
Meher Baba Kumar Nakka, M.S.(Pharm.), is a senior healthcare research & data analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this capacity, he works on a range of neurological indications, such as pain and migraine, and neurodegenerative disorders, such as Alzheimer’s disease. He holds a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad and a master’s degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research in Mohali.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.